These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 21872624)

  • 21. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones.
    Zensi A; Begley D; Pontikis C; Legros C; Mihoreanu L; Wagner S; Büchel C; von Briesen H; Kreuter J
    J Control Release; 2009 Jul; 137(1):78-86. PubMed ID: 19285109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. β-cyclodextrin-poly(β-amino ester) nanoparticles for sustained drug delivery across the blood-brain barrier.
    Gil ES; Wu L; Xu L; Lowe TL
    Biomacromolecules; 2012 Nov; 13(11):3533-41. PubMed ID: 23066958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential receptor-mediated drug targeting to the diseased brain.
    Rip J; Schenk GJ; de Boer AG
    Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug targeting to the brain.
    de Boer AG; Gaillard PJ
    Annu Rev Pharmacol Toxicol; 2007; 47():323-55. PubMed ID: 16961459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB).
    Kreuter J
    J Microencapsul; 2013; 30(1):49-54. PubMed ID: 22676632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier.
    Silva GA
    Surg Neurol; 2007 Feb; 67(2):113-6. PubMed ID: 17254859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategy for effective brain drug delivery.
    Alam MI; Beg S; Samad A; Baboota S; Kohli K; Ali J; Ahuja A; Akbar M
    Eur J Pharm Sci; 2010 Aug; 40(5):385-403. PubMed ID: 20497904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?
    Garcia-Garcia E; Andrieux K; Gil S; Couvreur P
    Int J Pharm; 2005 Jul; 298(2):274-92. PubMed ID: 15896933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shuttle-mediated nanoparticle delivery to the blood-brain barrier.
    Guarnieri D; Falanga A; Muscetti O; Tarallo R; Fusco S; Galdiero M; Galdiero S; Netti PA
    Small; 2013 Mar; 9(6):853-62. PubMed ID: 23135878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.
    Kreuter J; Hekmatara T; Dreis S; Vogel T; Gelperina S; Langer K
    J Control Release; 2007 Mar; 118(1):54-8. PubMed ID: 17250920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanostructure-based drug delivery systems for brain targeting.
    Haque S; Md S; Alam MI; Sahni JK; Ali J; Baboota S
    Drug Dev Ind Pharm; 2012 Apr; 38(4):387-411. PubMed ID: 21954902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB).
    Ulbrich K; Hekmatara T; Herbert E; Kreuter J
    Eur J Pharm Biopharm; 2009 Feb; 71(2):251-6. PubMed ID: 18805484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active targeting of brain tumors using nanocarriers.
    Béduneau A; Saulnier P; Benoit JP
    Biomaterials; 2007 Nov; 28(33):4947-67. PubMed ID: 17716726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound.
    Kinoshita M; McDannold N; Jolesz FA; Hynynen K
    Biochem Biophys Res Commun; 2006 Feb; 340(4):1085-90. PubMed ID: 16403441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier.
    Lu W; Tan YZ; Hu KL; Jiang XG
    Int J Pharm; 2005 May; 295(1-2):247-60. PubMed ID: 15848009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier.
    Qiao R; Jia Q; Hüwel S; Xia R; Liu T; Gao F; Galla HJ; Gao M
    ACS Nano; 2012 Apr; 6(4):3304-10. PubMed ID: 22443607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quaternary ammonium beta-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier.
    Gil ES; Li J; Xiao H; Lowe TL
    Biomacromolecules; 2009 Mar; 10(3):505-16. PubMed ID: 19216528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revisiting nanoparticle technology for blood-brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes.
    Johnsen KB; Moos T
    J Control Release; 2016 Jan; 222():32-46. PubMed ID: 26658072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier.
    Costantino L; Gandolfi F; Tosi G; Rivasi F; Vandelli MA; Forni F
    J Control Release; 2005 Nov; 108(1):84-96. PubMed ID: 16154222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier.
    Kuo YC; Lee CL
    Colloids Surf B Biointerfaces; 2012 Feb; 90():75-82. PubMed ID: 22024400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.